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Objectives
To present the baseline patient-reported outcome
measures (PROMs) in the Prostate Testing for
Cancer and Treatment (ProtecT) randomized trial
comparing active monitoring, radical prostatectomy and
external-beam conformal radiotherapy for localized
prostate cancer and to compare results with other
populations.
Materials and Methods
A total of 1643 randomized men, aged 50–69 years and
diagnosed with clinically localized disease identified by
prostate-specific antigen (PSA) testing, in nine UK cities in
the period 1999–2009 were included. Validated PROMs for
disease-specific (urinary, bowel and sexual function) and
condition-specific impact on quality of life (Expanded
Prostate Index Composite [EPIC], 2005 onwards;
International Consultation on Incontinence Questionnaire-
Urinary Incontinence [ICIQ-UI], 2001 onwards; the
International Continence Society short-form male survey
[ICSmaleSF]; anxiety and depression (Hospital Anxiety and
Depression Scale [HADS]), generic mental and physical
health (12-item short-form health survey [SF-12]; EuroQol
quality-of-life survey, the EQ-5D-3L) were assessed at
prostate biopsy clinics before randomization. Descriptive
statistics are presented by treatment allocation and by men’s
age at biopsy and PSA testing time points for selected
measures.
Results
A total of 1438 participants completed biopsy questionnaires
(88%) and 77–88% of these were analysed for individual
PROMs. Fewer than 1% of participants were using pads daily (5/
754). Storage lower urinary tract symptoms were frequent (e.g.
nocturia 22%, 312/1423). Bowel symptoms were rare, except for
loose stools (16%, 118/754). One third of participants reported
erectile dysfunction (241/735) and for 16% (118/731) this was a
moderate or large problem. Depression was infrequent (80/1399,
6%) but 20% of participants (278/1403) reported anxiety. Sexual
function and bother were markedly worse in older men (65–
70 years), whilst urinary bother and physical health were
somewhat worse than in younger men (49–54 years, all P <
0.001). Bowel health, urinary function and depression were
unaltered by age, whilst mental health and anxiety were better in
older men (P < 0.001). Only minor differences existed in mental
or physical health, anxiety and depression between PSA testing
and biopsy assessments.
Conclusion
The ProtecT trial baseline PROMs response rates were high.
Symptom frequencies and generic quality of life were similar
to those observed in populations screened for prostate cancer
and control subjects without cancer.
Keywords
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Urological Oncology
Introduction
Prostate cancer is the most commonly detected male
malignancy in many countries and accounted for 10 837
deaths in the UK in 2012 (Cancer Research UK: http://
www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/prostate-cancer). Prostate
cancer screening with PSA has been shown to identify
predominantly clinically localized disease in two randomized
trials of screening [1,2]. The main treatments for localized
prostate cancer are active surveillance, brachytherapy,
external-beam or intensity-modulated radiotherapy and open
or robot-assisted radical prostatectomy [3]. The optimum
treatment that balances the risks of the intervention and
disease control remains uncertain, although two randomized
trials of surgery and watchful waiting (supportive care with
treatment of symptoms as required) showed a disease-specific
survival benefit for radical intervention in the Scandinavian
SPCG-4 trial [4], but only for some men in the US PIVOT
trial [5].
Clinicians and patients selecting prostate cancer treatments
need robust information to enable them to balance symptom
and broader impact on quality of life (QoL) against mortality
and disease progression outcomes. Validated patient-reported
outcome measures (PROMs) [6] are the recommended tools
to assess the specific impacts of prostate cancer treatment on
incontinence, urinary irritation and obstruction, bowel-related
symptoms, sexual function and hormone therapy [7,8];
however, there has been limited use of validated PROMs in
localized prostate cancer trials, although recent radiotherapy
trials have incorporated PROMs [9]. One of the comparative
trials of surgery and watchful waiting for localized disease
measured symptoms with a Scandinavian questionnaire [10],
whilst the other trial used single items for urinary symptoms,
bowel and sexual function [5].
The UK National Institute for Health Research (NIHR)
Prostate Testing for Cancer and Treatment (ProtecT) trial
compares the effectiveness of active monitoring (a
surveillance strategy), radical prostatectomy and external-
beam conformal radiotherapy with neoadjuvant androgen
suppression for localized prostate cancer. The primary
outcome of prostate cancer-specific and intervention-related
mortality will be reported at a median 10 years’ follow-up in
2016. The present paper reports the baseline PROMs results
to assess their comparability with other studies and to
investigate the generalizability of the randomized population,
which will assist interpretation of the trial outcome results.
Materials and Methods
Study Design and Participants
The ProtecT trial design, baseline socio-demographic and
clinical results have been published elsewhere (Lane et al.;
protocol (http://www.nets.nihr.ac.uk/projects/hta/962099)]. A
feasibility pilot trial (recruitment: 1999–2001) preceded the
main trial (recruitment: 2001–2009) [11]. In brief, the trial
aimed to establish the effectiveness of radical prostatectomy,
external-beam conformal radiotherapy or active monitoring
for men with clinically localized prostate cancer. Men aged
50–69 years were invited for PSA testing in primary care, and
those with a PSA level ≥3.0 to 19.95 ng/mL proceeded to
further diagnostic tests, including prostate biopsies. Men with
clinically localized prostate cancer were eligible for
randomization if there were no major contra-indications for
the radical treatments (exclusions detailed previously) [11]. In
total, 2417 participants were identified with localized disease
(of 82 849 men PSA tested) and, of these, 1643 participants
were randomized to three treatments. The primary outcome
of definite or probable prostate cancer mortality (including
intervention related-mortality) at a median of 10 years’
follow-up and the secondary clinical, health economic and
patient-reported outcomes will be published in 2016 (trial
registration: ISRCTN 20141297, http://www.isrctn.com,
ClinicalTrials.gov NCT02044172).
Ethics
Approval was obtained from the UK National Health Service
Health Research Authority Multicentre Research Ethics
Committee (01/04/025).
Patient-Reported Outcomes Measures
Validated PROMs and their specific items (Table 1) were
selected using literature reviews and qualitative interviews with
participants [12] to capture the major impacts related to
prostate cancer treatments: urinary symptoms of incontinence
and erectile function after surgery; bowel function after
radiotherapy and anxiety or depression from living with
untreated cancer during active monitoring [7]. We also aimed
to assess the effects of ageing on urinary symptoms over time
and wider health issues using generic QoL measures. The trial
focused on treatments for localized disease so the Expanded
Prostate Index Composite (EPIC) hormonal domain was not
used, but this did not impact on the use of other domains,
which were scored separately [13]. The European Organisation
for Research and Treatment of Cancer Quality of Life
Questionnaire C-30 (EORTC-QLQC-30) [14], which has
symptom and functional scales, generic QoL and single items,
was used at 5 and 10 years’ follow-up (added in 2007).
Data Collection and Analysis
Participants completed paper questionnaires at initial PSA
testing (trial recruitment) and at first prostate biopsy clinics,
without reminders to non-responders (Fig. 1). The more
comprehensive set of assessments completed at first biopsy
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Design and baseline patient-reported outcomes in the ProtecT randomized trial
were taken as the baseline for subsequent trial outcome
analyses. Randomized participants completed postal
questionnaires at 6 months and then annually for at least
10 years (ongoing in 2016). Randomized non-responders
received reminder letters and questionnaires, followed by
telephone calls from trial nurses and then a shortened version
of the questionnaire with fewer measures. Some men were
not given the International Consultation on Incontinence
Questionnaire-Urinary Incontinence (ICIQ-UI; n = 135) or
EPIC (n = 794) measures as they were introduced in the trial
during 2001 and 2005, respectively. Data are presented for
the return of the PROMs questionnaire booklet and the
numbers which could be analysed for each PROM.
The PROMs were analysed as specified by the developers
with no additional imputation for missing data. To aid
interpretation of the results, the minimal clinically
important difference (MID) was calculated as half a
standard deviation of baseline values (a commonly used
distribution-based method), but unspecified by the
PROMs developers because MIDs are a more recently
utilized concept (Table 1). Categorical symptom variables
were dichotomized to ‘never or low/rarely’ vs ‘ever’ and
International Continence Society short-form male survey
(ICSmaleSF) items were dichotomized as previously in the
ProtecT trial pilot phase [20]. The number of men
without incontinence was defined as those with an ICIQ-
UI score of 0. Symptom-related QoL items were
categorized as none, small and a moderate/severe problem
attributable to expected low prevalence of symptoms
before treatment. Age was categorized into five-year
groups (49–54 years to 65–69 years, with one 49-year-old
who was eligible at recruitment). Self-reported ethnicity
was categorized using UK Office of National Statistics
census groupings (http://
webarchive.nationalarchives.gov.uk/20160105160709/http://
www.ons.gov.uk/ons/guide-method/measuring-equality/
equality/ethnic-nat-identity-religion/ethnic-group/
index.html). Socio-economic position was based on men’s
current or last paid occupation at recruitment, and was
grouped into professional or managerial (e.g. doctor),
intermediate (e.g. secretary) and routine or semi-routine
1643 participants randomly assigned 
Surgery(553)Radiotherapy (545)Active monitoring (545)
Prostate biopsy 
EPIC+, EQ-5D-3L, HADS, ICIQ-UI***, ICSmaleSF, SF-12
Questionnaire booklet returned (n = 1438/1643, 88%)
Annual measurement for at least 10 years
EORTC-QLQ-C30++, EPIC, EQ-5D-3L, HADS, ICIQ-UI, ICSmale SF, SF-12
PSA testing at recruitment
Clinical and demographic characteristics+
EQ-5D-3L, HADS,ICSmale*, SF-12 
Questionnaire booklet returned (n = 1562/1643**, 95%) 
Fig. 1 Flow diagram of PROMs completed by ProtecT randomised participants. +Collected by research nurses, *selected ICSmale-SF items, **SF-12 and
ICSmale as EQ5D-3L and HADS omitted for first 118 participants, +EPIC introduced in 2005, ***ICIQ-UI introduced in 2001, ++EORTC QLQ-C30 [19]
introduced in 2007.
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(e.g. postman) using the UK Office of National
Statistics categories [21].
Numbers and percentages are presented for categorical
data, means and SD values for continuous data, and
medians and interquartile ranges for skewed data. Those
PROMs with a skewed distribution of results (EPIC,
ICIQ-UI) as a result of few participants reporting
symptoms are presented as means to aid comparison
with other studies. Comparisons across age and
occupational social class used Cuzick’s test for trend
whilst Wilcoxon’s matched-pairs signed-rank tests
(ordinal/continuous data) and McNemar’s test (nominal
data) were used for comparisons of recruitment and
biopsy data. Variation in selected PROMs completed at
first biopsy (EPIC, Hospital Anxiety and Depression Scale
[HADS] and a 12-item short-form health survey [SF-12])
was explored according to men’s age at recruitment and
occupational social class and whether any differences
exceeded the MID. PROMs data collected at PSA testing
and biopsy time points were compared, and a sensitivity
analysis subsequently assessed the impact of adding PSA
testing data if the data from the biopsy time point were
missing. All analyses were performed in STATA (version
13).
Results
Study and Participant Characteristics and PROMs
Completion
The median age of randomized participants was 61 years,
the majority were married or co-habiting (84%, 1375) and
of white ethnicity (99%, 1606; full baseline demographic
and clinical details published elsewhere) [11].
Approximately two fifths of participants reported a
professional or managerial occupation (42%, 684/1643),
16% (259) an intermediate occupation and 42% (678) a
routine or semi-routine occupation. Most randomized
participants had low-risk disease features at diagnosis, as
the median PSA at PSA testing was 4.6 ng/mL and around
three quarters had a Gleason score of 6 (77%, 1266) and
clinical stage of T1c (76%, 1249).
The majority of participants returned a questionnaire
booklet at PSA testing (recruitment, 95%) and first biopsy
clinics (88%, Fig. 1). Data that could be analysed for
measures completed at first biopsy ranged from 77% for
the SF-12 to 88% for EPIC bowel and urinary function
(Table 1). As EPIC was introduced during the trial, 52% of
randomized participants were asked to complete all
PROMs at baseline (849/1643). Response rates for all
PROMs were similar by randomized treatment allocation
(Tables 2–4).
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Design and baseline patient-reported outcomes in the ProtecT randomized trial
Urinary, Bowel and Sexual Dysfunction and their
QoL Impact
Levels of incontinence were low, indicating few problems, and
at baseline <1% of men reported incontinence as a large
problem (4/1259 [Table 2]) at diagnosis. Fewer than 1% of
men reported using at least one pad per day (5/754). Seventy
percent of the participants reported being incontinence-free
(873/1244). Urinary function was good (EPIC score 95.1) and
bother related to urinary symptoms was low (EPIC score
91.0), with few irritative or obstructive symptoms (EPIC score
93.0), as measured by EPIC. Nocturia was reported by around
one fifth of men (312/1423; ICSmaleSF) and around one third
also reported a regular daytime frequency (460/1410),
although only 3% of men (44/1427) reported these LUTS as
being a moderate or severe problem (ICSmaleSF).
Bowel symptom EPIC scores were good (i.e. few problems)
and only 3% of men (20/751) reported a moderate or large
problem attributable to bowel symptoms (Table 3). The
frequency of faecal incontinence or bloody stools was also
low, although 16% of participants reported having loose
stools at least half of the time (118/754).
Around one third of men (241/735) reported erectile
dysfunction and for 16% of participants this was a moderate
or large problem (118/731) with the EPIC measure. Sexual
function and bother scores were much lower than for
urinary and bowel symptoms as assessed by EPIC (Tables 2
and 3).
Generic Health Status, Anxiety and Depression
Generic physical and mental health sub-scores were similar
with UK normative data (SF-12 sub-scores of 50 [Table 4])
[18]. The EuroQoL health utility scale, the EQ-5D-3L, also
indicated good overall health (score 0.89). Mean anxiety and
depression scores were low, although one fifth of men (278/
Table 3 Bowel and sexual function by randomized allocation in ProtecT trial participants.
EPIC* summary scores (SD) and
specific symptoms (%)
Active monitoring (n = 545) Radiotherapy (n = 545) Surgery (n = 553) Total (n = 1643)
Bowel function
Minimum analysed/asked, n/N (%) 247/280 (88) 247/283 (87) 254/286 (89) 748/849 (88)
Summary score 92.8 (9.1) 94.8 (6.9) 93.1 (8.9) 93.6 (8.4)
Function score 91.6 (9.0) 92.9 (8.0) 91.4 (9.3) 92.0 (8.8)
Bother score 94.0 (11.8) 96.8 (7.1) 94.7 (10.3) 95.1 (10.0)
Bloody stools, n/N (%) 18/247 (7) 18/250 (7) 16/255 (6) 52/752 (7)
Loose stools, n/N (%) 43/249 (17) 39/250 (16) 36/255 (14) 118/754 (16)
Stool leakage, n/N (%) 10/249 (4) 3/250 (1) 10/255 (4) 23/754 (3)
Overall bowel problems: small, n/N (%) 32/249 (13) 18/247 (7) 35/255 (14) 85/751 (11)
Moderate/big bowel problems, n/N (%) 11/249 (4) 4/247 (2) 5/255 (2) 20/751 (3)
Sexual function
Minimum analysed/asked, n/N (%) 236/280 (84) 241/283 (85) 240/286 (84) 719/849 (85)
Summary score 60.3 (23.5) 63.6 (23.1) 61.4 (22.7) 61.8 (23.1)
Function score 53.5 (22.8) 55.7 (23.0) 54.4 (22.9) 54.5 (22.9)
Bother score 76.0 (30.5) 80.5 (29.2) 77.6 (28.9) 78.0 (29.5)
Erectile function, n/N (%) 79/243 (33) 78/247 (32) 84/245 (34) 241/735 (33)
Erectile problems: small 70/239 (29) 55/245 (22) 63/247 (26) 188/731 (26)
Erectile problems: moderate/big 39/239 (16) 39/245 (16) 40/247 (16) 118/731 (16)
Overall sexuality problem: small 55/239 (23) 58/244 (24) 69/245 (28) 182/728 (25)
Moderate/big sexuality problems 44/239 (18) 31/244 (13) 39/245 (16) 114/728 (16)
EPIC, Expanded Prostate cancer Index Composite; MID, minimal clinically important difference; PROM, patient-reported outcome measure. *Details of PROMs and their
administration in Table 1 and Fig. 1; the MID was not exceeded for any domain between randomized groups.
Table 4 Health-related quality of life and psychological status in men randomized in the ProtecT trial.
Summary EPIC* scores (SD) or case (%) Active monitoring N = 545 Radiotherapy N = 545 Surgery N = 553 Total N = 1643
SF-12 minimum analysed, n (%) 418 (77) 410 (75) 432 (78) 1260 (77)
Mental health score 53. 4 (8.2) 54.5 (6.3) 53.9 (7.9) 53.9 (7.5)
Physical health score 50.4 (8.7) 51.7 (7.0) 51.4 (7.9) 51.2 (7.9)
HADS minimum analysed, n (%) 469 (86) 454 (83) 472 (85) 1399 (85)
Anxiety score 5.1 (3.6) 4.5 (3.2) 5.0 (3.6) 4.9 (3.5)
Depression score 2.7 (2.7) 2.3 (2.4) 2.4 (2.5) 2.5 (2.5)
Anxiety possible case, n/N (%) 107/472 (23) 74/454 (16) 97/477 (20) 278/1403 (20)
Depression possible case, n/N (%) 37/469 (8) 17/458 (4) 26/472 (6) 80/1399 (6)
EQ-5D-3L analysed, n (%) 474 (87) 458 (84) 481 (87) 1413 (86)
Health utility 0.87 (0.19) 0.90 (0.16) 0.88 (0.17) 0.89 (0.17)
EPIC, Expanded Prostate cancer Index Composite; MID, EQ-5D-3L, EuroQol quality-of-life survey; HADS, Hospital Anxiety and Depression Scale; SF-12, 12-item short-form health
survey. *Details of PROMs and their administration in Table 1 and Fig. 1; the MID was not exceeded for any domain between randomized groups.
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1403) had possible clinical levels of anxiety and ~6% of men
had depression (80/1399 [Table 4]).
Symptoms and Quality of Life by Age and
Occupational Social Class
Urinary EPIC summary and bother scores were generally
worse in older men than younger men, unlike urinary
function, and all bowel scores (where there was no
difference with age), but differences in urinary scores did
not exceed the MID (Table 5 and Fig. 2). The EPIC sexual
summary, function and bother scores were better in the
youngest (49–54 years) men compared with the oldest age
group (65–69 years), and these differences in summary and
functional scores exceeded the MID (Table 5). Anxiety was
less frequent in older men, unlike depression which was
similar across all age groups. In older men, physical health
was worse than in younger men, whilst mental health was
better (Table 5) although none of these differences
exceeded the MID for HADS and SF-12. There were no
strong associations of socio-economic status with quality of
life, although there was some evidence of higher levels of
depression and reduced bowel function with lower status,
but neither exceeded the MID (Table S1). There was no
evidence that physical health differed by socio-economic
status.
Generic Physical and Mental Health at PSA Testing
and Biopsy
There were no differences in overall mental health (SF-12),
and minor differences which did not exceed the MID in
physical health (SF-12 < 2 scale points), nor in anxiety
(<0.2 points) and depression (0.5 points) at PSA testing
and first biopsy clinics (data not shown). The addition of
PSA testing PROM data if biopsy PROM data were
missing (e.g. an extra 188 participants for the anxiety
score) did not alter the biopsy results (data not shown), so
this approach was used in the trial outcome analyses (R.
Pickard, M. Fabricus & E. McColl, unpublished data).
Discussion
There was good completion of a comprehensive range of
validated PROMs at diagnostic biopsy before
randomization to treatments for localized prostate cancer
in the ProtecT trial. Urinary and bowel symptoms were
generally infrequent (apart from storage LUTS), whilst
sexual dysfunction was reported by around one third of
men. Urinary and sexual function were generally worse
in older men (65–69 years) than younger men (49–
54 years) with clinically important reductions (MID) in
sexual function, unlike bowel function where there were
no age-related effects. Anxiety and depression were
reported in around one fifth and one twentieth of
participants, respectively. Overall physical and mental
health scores were similar to national normative data.
There were no large differences in mental or physical
health, anxiety or depression between PSA testing and
biopsy assessments. These data, therefore, confirm that
the men randomized in the ProtecT study were generally
healthy and mostly asymptomatic.
Interpretation of the ProtecT trial clinical results will be
enhanced by the use of validated PROMs with pretreatment
measurements (recommended by the CONSORT-PRO
guidelines) [6] and high response rates. The ProtecT trial
results are based on men identified by community-based PSA
testing and are hence analogous to screen-detected patients
Table 5 Symptoms and quality of life by age group in men randomized in the ProtecT trial.
Age group 49–54 years 55–59 years 60–64 years 65–70 years P*
Symptoms (MID)†
Minimum analysed/asked, n/N (%) 76/87 (87) 200/225 (89) 220/270 (81) 223/267 (84)
Urinary summary (4.6) 93.1 (9.9) 94.0 (7.2) 92.2 (9.5) 92.0 (9.9) 0.022
Urinary function (4.2) 92.9 (12.8) 95.7 (7.0) 94.9 (8.0) 95.3 (8.1) 0.627
Urinary bother (5.9) 93.3 (10.3) 92.7 (9.2) 90.2 (12.4) 89.6 (13.1) <0.001
Bowel summary (4.2) 93.7 (10.3) 93.1 (8.6) 93.1 (8.2) 94.4 (7.6) 0.357
Bowel function (4.4) 91.7 (11.1) 91.3 (9.0) 91.6 (8.7) 93.0 (7.9) 0.170
Bowel bother (5.0) 95.4 (11.6) 94.9 (9.8) 94.7 (10.0) 95.7 (9.7) 0.755
Sexual summary score (11.6) 72.9 (20.6) 65.8 (21.0) 60.0 (23.2) 56.2 (23.8) <0.001
Sexual function score (11.5) score 66.1 (21.2) 58.8 (20.3) 53.0 (22.4) 48.3 (24.0) <0.001
Sexual bother score (14.8) 87.9 (24.1) 81.1 (28.0) 75.9 (30.8) 74.0 (30.4) <0.001
Mental/physical health†(MID), n/N (%) 142/189 (75) 346/418 (83) 403/532 (76) 369/504 (73)
Anxiety score (1.8)‡ 5.5 (3.5) 5.2 (3.5) 4.8 (3.6) 4.5 (3.3) <0.001
Depression score (1.3)‡ 2.5 (2.8) 2.4 (2.7) 2.5 (2.5) 2.4 (2.3) 0.123
Mental health score (3.8)§ 51.9 (9.2) 53.3 (7.3) 53.9 (7.7) 55.3 (6.5) <0.001
Physical health score (4.0)§ 52.9 (7.6) 51.6 (7.8) 50.9 (8.0) 50.3 (7.9) <0.001
HADS, Hospital Anxiety and Depression Scale; MID, minimal clinically important difference; PROM, patient-reported outcome measure; SF-12, 12-item short-form health survey.
Data are EPIC summary scores (SD), unless otherwise indicated. *Cuzick’s test; MID 0.5 SD of baseline values with domains in bold where exceeded between youngest and oldest age
groups. †Details of PROMs and their administration in Table 1 and Fig. 1; ‡HADS; §SF-12;
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with largely low-risk disease, which reflects contemporary
practice in many countries, unlike the earlier SPCG-4 trial
[4]. The comprehensive range of PROMs encompasses the
domains identified to assess treatments for prostate cancer by
the National Cancer Institute prostate cancer working group
[7], the International Consortium for Health Outcome
Measurements for prostate cancer [8] and the ongoing core
outcome set for localized prostate cancer trials which used
mixed methods to reach consensus (MacLennan SJ et al. Core
outcome set for trials of interventions for localized prostate
cancer, unpublished data). The EPIC-26 PROM (a shorter
version of EPIC) is now recommended for assessing prostate
cancer treatments [8] and EPIC was added to the trial in
2005, so the majority of participants will have outcome
assessments using this measure. Overall QoL and
psychological PROMs also assessed the broader impacts of
prostate cancer treatment, unlike in many previous studies
[22–24].
There are some potential limitations to these baseline results
in that the characteristics of non-responders to questionnaires
were not compared with those of responders, although major
differences are unlikely given the high response rates. Less
severe psychological impacts may have been overlooked as
the HADS was developed to detect clinical depression and
anxiety [17]. Psychological distress was reported by around
one fifth of ProtecT trial participants (33/171) completing the
Impact of Events Scale at PSA testing and biopsies in a sub-
study [25], which was similar to the frequency of anxiety
reported with HADS in the present study by randomized
participants. Baseline PROMs assessments occurred during
the diagnostic process, which may have influenced
participants’ perceptions of symptoms but were needed before
randomization and there were also only minor differences
between PSA and biopsy assessments. Furthermore, we
present MIDs to aid interpretation and comparison with
other findings but these PROMs were developed before the
MID concept was widespread and this had not been validated
nor was it in the prespecified trial analysis plan.
The applicability of the present results to men of non-white
ethnicity is unclear, as ProtecT trial participants were mostly
of white ethnicity. The percentage of white participants in the
trial was broadly similar to the older male population at
seven of the cities in the ProtecT trial (UK census data),
whilst the percentage of black participants was lower than in
the population of one city and Asian men in two cities.
Participants in screening trials are often healthier than the
general population and, in the European Randomised
Screening for Prostate Cancer (ERSPC) trial screened arm,
cardiovascular mortality was lower than in the unscreened
arm [26]. The ProtecT trial baseline overall physical and
mental health and HADS scores in randomized participants
were similar to UK population data [18,27], as was broadly
the dietary energy intakes of ProtecT participants with
prostate cancer [28]. The socio-economic distribution of
randomized participants in the ProtecT trial is similar to
national data (e.g. 39% of men aged 55–64 years with a
professional occupation in census data compared with 42% in
ProtecT trial participants) [21].
The ProtecT trial baseline PROM results could be compared
either with men undergoing prostate cancer screening prior
to prostate cancer treatment or men with benign urological
conditions or community-based populations. ERSPC
participants without prostate cancer reported good urinary
and bowel function, low bother (EPIC score) and reduced
sexual function, which worsened in older men (Dutch
questionnaire) [29] in a similar manner to randomized
participants in the ProtecT trial. There were few changes in
quality of life and anxiety during ERSPC screening [30,31]
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Fig. 2 Urinary, bowel and sexual function and bother by age in randomized participants in the ProtecT trial. Details of Expanded Prostate Index
Composite (EPIC) administration in Table 1 and Fig. 1, y-axis 0–40 not shown.
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and their SF-36 scores were consistent with the ProtecT trial
SF-12 scores at PSA testing and biopsy (scoring equivalency
exists between questionnaires [32]). Men with high levels of
anxiety during ERSPC screening were predicted to have high
anxiety at recruitment [33], which was also observed in the
wider ProtecT trial cohort [25]. Non-cancer controls in the
American Prostate Lung and Colorectal Cancer screening trial
showed similar patterns of bowel, sexual and urinary
symptoms (EPIC score) to those of men in ProtecT trial at
baseline [34].
None of the major localized prostate cancer trials [4,5,35]
comparing treatments include baseline assessments made
before treatment, unlike several prostate cancer cohorts. Rates
of erectile function, pad use (1%) and problematic urinary
symptoms (2%) in US patients before treatment, measured
with EPIC-26 [36], were similar to baseline ProtecT trial
findings. Dutch patients subsequently undergoing surgery or
radiotherapy also had similar levels of pad use, a slightly
lower frequency of loose stools (10%) and greater erectile
dysfunction (~50%) [37] than results presented here.
American prostate cancer cohorts that recruited either in
1994 to 1995 (Prostate Cancer Outcomes Study [PCOS]) or
2011 to 2012 (Comparative Effectiveness Analysis of Surgery
and Radiation [CEASAR]), with baseline assessments made
by recalling symptoms before diagnosis with the University of
California Los Angeles Prostate Cancer Index (UCLA-PCI, a
precursor to EPIC) and EPIC-26, respectively, were compared
for patterns over time [38]. Incontinence was relatively
frequent but was higher in the newer cohort (CEASAR: 27%,
PCOS 19%), whilst pad use was higher in both cohorts than
reported here (CEASAR: 7%, PCOS 3%). Erectile dysfunction
was very prevalent in the recent CESAR cohort (45%, PCOS:
24%) and the ProtecT trial baseline results at around one
third of men was broadly similar to both cohorts. Bowel
function was good in the CESAR cohort [39] but was not
compared with PCOS because the UCLA-PCI did not include
all the bowel questions included in the EPIC score.
An Australian cohort of men without prostate cancer
(matched to men with the disease) [40] showed similar levels
of incontinence (1% pad use), a slightly higher percentage of
major bowel problems (6%) and similar erectile dysfunction
(22%), assessed using the UCLA-PCI, to those seen in the
participants of the ProtecT trial men at baseline. The
prevalence of LUTS increased with age and was up to 30% in
men aged >80 years, based on UK general practice data [41].
Some symptom PROMs used in the ProtecT trial were
validated with clinical or community populations, e.g. ICIQ-
UI where the community sample incontinence score (1.6) was
similar to the ProtecT trial results in the present study, and
was lower than for urology clinic attendees (2.4) [15]. Men
listed for surgery for LUTS had a mean incontinence score of
4.0 and a voiding score of 8.9 (ICSmaleSF) [16], which
indicated worse symptoms than for participants in the
ProtecT trial before treatment. The UCLA-PCI results for US
men without cancer were very similar to ProtecT trial
baseline results [42], except that bowel function and bother
were worse in older men, possibly because the mean age of
older men completing UCLA-PCI was 79 years, which
exceeded the upper age limit for ProtecT trial men (69 years).
The EPIC sexual function scores of older men in the ProtecT
trial were below a clinical threshold for potency (EPIC sexual
domain score of <60) [43].
In conclusion, there were generally low levels of urological
and bowel symptoms but more erectile dysfunction in
participants before randomization and treatment for localized
prostate cancer in the ProtecT trial. Symptom frequencies and
trends with age were similar to those found in other cohorts.
These results help characterize the trial population and will
facilitate the robust evaluation of treatment impacts when the
ProtecT trial outcomes are published in 2016.
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